Suzhou Fushilai Pharmaceutical Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Suzhou Fujilai Pharmaceutical Co., Ltd., formerly known as Changshu Fujilai Pharmaceutical Chemical Co., Ltd., has gradually expanded from an initial area of only over 10 acres to over 100 acres. The company is located at No. 16 Haiwang Road, Changshu New Materials Industrial Park, Changshu City, Jiangsu Province. The company mainly produces three major products: lipoic acid series, carnosine series, and phosphatidylcholine series, all of which are encouraged "biopharmaceutical" high-tech products. The product is mainly used in medicine, dietary supplements, cosmetics and other fields. It has remarkable effects in anti-oxidation, anti-aging, blood sugar improvement and other aspects. In recent years, the company has developed rapidly and has become a dark horse in the same industry in China. It has also become one of the largest professional manufacturers in China specializing in the production of three major series of raw materials (pharmaceutical intermediates), including lipoic acid series products, carnosine series products, and phosphatidylcholine series. Our products are mainly exported and have been exported to foreign markets such as Europe, America, and Southeast Asia. We have established long-term supply and sales cooperation with relevant foreign merchants. For many years, the company has focused on reducing pollution at the source, reducing pollution during the process, and adopting advanced and effective terminal treatment to achieve micro discharge of wastewater and total pollution control. We have obtained multiple invention patents and have been awarded by superior departments at the provincial and municipal levels. The China Environment Daily gave a special report. The company implements complete quality management and organizes production according to GMP requirements. It has passed the GMP certification for pharmaceutical raw materials and on-site inspections by the US FDA. |
| Headquarter | Suzhou |
| Establish Date | 11/27/2000 |
| Listed Code | 301258.SZ |
| Listed Date | 3/29/2022 |
| Chairman | Qian Xiangyun. |
| CEO | Qian Xiangyun. |
| Website | www.fuslai.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
